| Document |
Document Title |
|
WO/2018/165895A1 |
Provided is an isolated CTLA4 monoclonal antibody. The antibody can highly-specifically bind to CTLA4, and can effectively block the binding of CLTA4 to B7, reduce the activity or expression level of CTLA4, relieve the inhibition of CTLA...
|
|
WO/2018/167317A1 |
The present invention relates to a method of hematopoietic stem cell generation, comprising the steps of providing a hematopoietic stem cell isolate from a donor and expanding said hematopoietic stem cells in vitro in the presence of a c...
|
|
WO/2018/170412A1 |
A microfluidic biochip device includes a housing including at least one microchannel defining at least one cell adhesion region. The at least one cell adhesion region is provided with at least one capturing agent that adheres a cell of i...
|
|
WO/2018/169793A1 |
The present disclosure relates generally to methods for treating leukemia in a subject in need thereof comprising administering to the subject an effective amount of hematopoietic cells obtained from a candidate donor having a specific c...
|
|
WO/2018/165913A1 |
Provided are a specific chimeric antigen receptor targeting NKG2DL and a CAR-T cell thereof, as well as a preparation method and the use thereof. The CAR-T cell can effectively target and attack a plurality of tumour cells, and can be us...
|
|
WO/2018/170139A1 |
The invention relates to culturing motor neuron cells together with skeletal muscle cells in a fluidic device under conditions whereby the interaction of these cells mimic the structure and function of the neuromuscular junction (NMJ) pr...
|
|
WO/2018/170046A1 |
Described herein is a managed, indexed repository of hematopoietic stem cell (HSC) lines and/or blood progenitor cell lines derived from induced pluripotent stem cells (iPSCs) (or embryoid bodies formed from iPSCs), wherein each of the H...
|
|
WO/2018/166307A1 |
Disclosed are a specific chimeric antigen receptor targeting NKG2DL, a coding sequence thereof, and immune response cells modified by same, and the preparation method and use thereof. The modified immune response cells can effectively ta...
|
|
WO/2018/169094A1 |
[Problem] An objective of the present invention is to obtain immortalized human-derived tumor vascular endothelial cells which are useful in cell based experiments such as compound screening. [Solution] The present invention pertains to ...
|
|
WO/2018/166495A1 |
Provided is an isolated TrkB agonist antibody that binds to an epitope contained in one of the extracellular domains of TrkB and is capable of activating TrkB, wherein the extracellular domains comprises extracellular D1, D2, D3, D4, D5 ...
|
|
WO/2018/170335A1 |
The present disclosure provides distinct therapeutic populations of cells that form a pharmaceutical composition useful in hematopoietic stem/progenitor cell transplant. For example, the present disclosure provides a therapeutic populati...
|
|
WO/2018/169058A1 |
The present invention addresses the problem of providing a RNA-binding protein having solubility and high affinity. According to the present invention, there is provided a RNA-binding protein having an amino acid sequence represented by ...
|
|
WO/2018/168983A1 |
The purpose of the present invention is to provide a sheet-shaped cell culture having a high mechanical strength and a method for producing the same. This problem is solved by providing a method for producing a sheet-shaped cell culture,...
|
|
WO/2018/170015A1 |
Described herein are methods of avoiding an immune response in a subject being administered a regimen requiring Cas9 in order to optimize and broaden the application of CRIPSR based therapeutics comprising administering immune orthogonal...
|
|
WO/2018/169060A1 |
The present invention addresses the problem of providing: a method for efficiently separating megakaryocytes from platelets produced from the megakaryocytes; and a platelet separation kit for efficiently separating megakaryocytes from pl...
|
|
WO/2018/169065A1 |
The present invention addresses the problem of providing a method with which it is possible to uniformly produce cell structures in a short time and in large quantities. According to the present invention, there is provided a method for ...
|
|
WO/2018/167057A1 |
The present invention refers to human microRNA hsa-miR-665 for the treatment or prevention of heart diseases associated with cardiac hypertrophy and consequent pathological remodeling of the heart, in particular for preventing and/or tre...
|
|
WO/2018/168958A1 |
Provided is a novel heat-resistant luciferase. Mutant luciferase of (a) or (b) below. (a) A mutant of wild-type luciferase comprising the amino acid sequence of SEQ ID NO: 1, wherein phenylalanine 292 and/or phenylalanine 294 in the amin...
|
|
WO/2018/168955A1 |
On the basis of the above-mentioned problem that the present inventors have newly found now, an evaluation system is provided, in which a reaction of cells, which is closer to an in vivo reaction of the cells, can be induced in vitro. Pr...
|
|
WO/2018/165997A1 |
A formula of a serum-free medium for human pluripotent stem cells, comprising the following raw materials: an inorganic salt composition, an organic matter composition, amino acid, amino acid salt, energy substance, metabolic intermediat...
|
|
WO/2018/170394A1 |
Compositions of insulin-secreting cells and stem cells and methods for their use as well as use of insulin and stem cell products in wound healing and/or reducing scar and/or scab formation are provided.
|
|
WO/2018/170390A1 |
Provided herein are methods and compositions for dynamically controlling and targeting multiple arms of the immune system. Some aspects provide mesenchymal stem cells (MSCs) engineered to produce multiple effector molecules. In some inst...
|
|
WO/2018/170309A1 |
The disclosure concerns a method for cancer treatment by in vivo priming and activation of natural killer cells for achieving tumor cell lysis. The method includes introducing into a patient a priming tumor cell preparation (PTCP) derive...
|
|
WO/2018/170172A1 |
The present disclosure encompasses methods for generating cells or tissue from existing cells with one or more mutated variants of Yap. In specific embodiments, the disclosure regards treatment of existing cardiomyocytes with one or more...
|
|
WO/2018/170164A1 |
Disclosed herein are methods for the generation of highly accurate nucleic acid libraries encoding for predetermined variants of a nucleic acid sequence. The degree of variation may be complete, resulting in a saturated variant library, ...
|
|
WO/2018/170484A1 |
Provided herein is a scaffold comprising a decellularized meniscus tissue, wherein the scaffold is covalently conjugated with heparin and a growth factor. Also provided herein is a method of repairing and/or treating a tissue injury in a...
|
|
WO/2018/168829A1 |
A production method for helper T cells, the method including: (i) a step in which T cells that have been induced from pluripotent stem cells and have had the CD4 gene or the product of said gene introduced thereinto are cultured in a cul...
|
|
WO/2018/168801A1 |
Provided is a mutant histidine decarboxylase suitable for practical use. More specifically, provided are a mutant histidine decarboxylase and use of the same, said mutant histidine decarboxylase having a mutation in at least one amino ac...
|
|
WO/2018/169007A1 |
The present invention addresses the problem of providing a method for forming a cell mass by three-dimensional culture of primary cancer cells using a tumor tissue as a starting material while inhibiting the proliferation of cells (e.g.,...
|
|
WO/2018/170338A2 |
The present disclosure provides TCRs with high or enhanced affinity against various tumor associated antigens (including human MAGE-A1 epitopes), T cells expressing such high affinity antigen specific TCRs, nucleic acids encoding the sam...
|
|
WO/2018/167149A1 |
The present invention relates to a method for irradiating a population of mammalian cells comprising at least one target mammalian cell with electron beams and/or X-rays, characterized in that: (i) a composition comprising a population o...
|
|
WO/2018/169948A1 |
Disclosed are methods of eliminating at least one target cell in a subject, comprising administering to the subject an effective amount of a composition comprising a plurality of immune cells, wherein each immune cell of the plurality ex...
|
|
WO/2018/169994A1 |
Disclosed herein are methods of treating cancer by increasing mRNA m6A methylation level and/or decreasing mRNA m6A demethylation in cancer stem cells. The methods entail administering an effective amount of one or more therapeutic agent...
|
|
WO/2018/169554A1 |
The present invention relates to methods, systems, factors, and media for the reduction of cellular stress and reduction of the amount reactive oxygen species. Embodiments of the invention reduce cellular stress by treating cells with a ...
|
|
WO/2018/161135A1 |
The present invention describes i) the construction of synthetic genes for components of a recombinant fibrin glue: fibrinogen A, fibrinogen B, fibrinogen G, factor XIIIA, prothrombin, ecarin and ERp57; ii) the expression of said genes i...
|
|
WO/2018/164281A1 |
Provided is a method whereby fruits, etc. are modified by electrically stimulating an orchard tree such as grape or a vegetable to thereby achieve modification effects of, for example, improving the disease resistance, enhancing the repe...
|
|
WO/2018/165194A1 |
Provided herein are engineered cells and methods for engineering cells to deliver a therapeutic agent, e.g., a small molecule, peptide or other drug, to a cell or tissue to be treated.
|
|
WO/2018/162722A1 |
The present disclosure provides DPP-4 inhibitors for use in treating a bone fracture, for use in preventing non-union of a bone fracture or preventing healing complications following bone fracture, for use in reducing the inhibitory effe...
|
|
WO/2018/164098A1 |
Provided is a heart fiberization model which is more closely similar to a myocardial tissue. A cell population which can be obtained by culturing a cell population containing pluripotent stem cell-derived cardiomyocytes in the presence o...
|
|
WO/2018/165291A1 |
Provided herein are populations of modified NK-92 cells, compositions and kits comprising the cells, and methods of making and using the populations of cells.
|
|
WO/2018/165228A1 |
Disclosed herein are immunostimulatory cells recombinantly engineered for adoptive cellular therapy. Additionally provided are pharmaceutical compositions comprising such immunostimulatory cells and methods of using such immunostimulator...
|
|
WO/2018/164040A1 |
To produce a large quantity of healthy, functional platelets. A method for producing platelets that includes (1) a culture step for culturing megakaryocyte cells in platelet production medium in the presence of physical stimulation and p...
|
|
WO/2018/165198A1 |
Provided herein are engineered cells and methods for engineering cells to deliver a therapeutic agent, e.g., a small molecule, peptide or other drug, to a cell or tissue to be treated.
|
|
WO/2018/162346A1 |
The invention relates to a culture medium, preferably a cell culture medium, comprising at least one oligopeptide of 2-10 amino acids in length, said amino acids being natural amino acids and at least one of said amino acids being lysine...
|
|
WO/2018/161418A1 |
Provided are a humanized mouse model for hepatitis B constructed by using stem cells and an application thereof. The humanized mouse model for hepatitis B is constructed by means of obtaining human stem cells, implanting the human stem c...
|
|
WO/2018/162563A1 |
The invention relates to a method of isolating a T cell that expresses a T cell receptor capable of binding specifically to an antigen presented by a cancer cell in association with an MR molecule. The method comprises the steps of (a) p...
|
|
WO/2018/165308A1 |
A bioreactor including a bioreactor body, wherein the bioreactor body includes a first substrate and an opposing second substrate, a pathway extending through the bioreactor body and being formed by a first channel defined in the first s...
|
|
WO/2018/164240A1 |
The present invention provides a method for producing retinal pigment epithelial cells including the following steps: (1) a first step for culturing pluripotent stem cells for a period that does not exceed 30 days by using a medium conta...
|
|
WO/2018/161417A1 |
Provided is a method for constructing a humanized mouse model for chronic hepatitis B by using stem cells. The method comprises obtaining human stem cells, transplanting the stem cells into a mouse with liver damage, infecting a humanize...
|
|
WO/2018/162623A1 |
The present invention relates to 3D cell cultures, which contain hepatic cells and are infected by a pathogen, methods for preparing such cell cultures and uses thereof.
|
